Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study.

Stark K, Reinhard W, Neureuther K, Wiedmann S, Sedlacek K, Baessler A, Fischer M, Weber S, Kaess B, Erdmann J, Schunkert H, Hengstenberg C.

PLoS One. 2008 Apr 9;3(4):e1948. doi: 10.1371/journal.pone.0001948.

2.

Polymorphisms associated with cholesterol and risk of cardiovascular events.

Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M.

N Engl J Med. 2008 Mar 20;358(12):1240-9. doi: 10.1056/NEJMoa0706728.

3.

Control of renal uric acid excretion and gout.

Taniguchi A, Kamatani N.

Curr Opin Rheumatol. 2008 Mar;20(2):192-7. doi: 10.1097/BOR.0b013e3282f33f87. Review.

PMID:
18349750
4.

Disease-related and all-cause health care costs of elderly patients with gout.

Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.

J Manag Care Pharm. 2008 Mar;14(2):164-75.

5.

SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.

Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF.

Nat Genet. 2008 Apr;40(4):437-42. doi: 10.1038/ng.106. Epub 2008 Mar 9.

PMID:
18327257
6.

SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.

Döring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, Paulweber B, Pfeufer A, Rosskopf D, Völzke H, Illig T, Meitinger T, Wichmann HE, Meisinger C.

Nat Genet. 2008 Apr;40(4):430-6. doi: 10.1038/ng.107. Epub 2008 Mar 9.

PMID:
18327256
7.

Multiple organic anion transporters contribute to net renal excretion of uric acid.

Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G, Barshop BA, Nigam SK.

Physiol Genomics. 2008 Apr 22;33(2):180-92. doi: 10.1152/physiolgenomics.00207.2007. Epub 2008 Feb 12.

8.

Gout in ambulatory care settings in the United States.

Krishnan E, Lienesch D, Kwoh CK.

J Rheumatol. 2008 Mar;35(3):498-501. Epub 2008 Feb 1.

PMID:
18260174
9.

Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.

Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M, Ahmadi K, Dobson RJ, Marçano AC, Hajat C, Burton P, Deloukas P, Brown M, Connell JM, Dominiczak A, Lathrop GM, Webster J, Farrall M, Spector T, Samani NJ, Caulfield MJ, Munroe PB.

Am J Hum Genet. 2008 Jan;82(1):139-49. doi: 10.1016/j.ajhg.2007.11.001.

10.

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.

Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F; National Arthritis Data Workgroup.

Arthritis Rheum. 2008 Jan;58(1):26-35. doi: 10.1002/art.23176.

11.

The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.

Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, Lai S, Dei M, Orrù M, Albai G, Bandinelli S, Schlessinger D, Lakatta E, Scuteri A, Najjar SS, Guralnik J, Naitza S, Crisponi L, Cao A, Abecasis G, Ferrucci L, Uda M, Chen WM, Nagaraja R.

PLoS Genet. 2007 Nov;3(11):e194.

12.

The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, Russel FG, Masereeuw R.

Kidney Int. 2008 Jan;73(2):220-5. Epub 2007 Oct 31.

13.

The Rotterdam Study: objectives and design update.

Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC.

Eur J Epidemiol. 2007;22(11):819-29. Epub 2007 Oct 23.

14.

PLINK: a tool set for whole-genome association and population-based linkage analyses.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC.

Am J Hum Genet. 2007 Sep;81(3):559-75. Epub 2007 Jul 25.

15.

The changing epidemiology of gout.

Roddy E, Zhang W, Doherty M.

Nat Clin Pract Rheumatol. 2007 Aug;3(8):443-9. Review.

PMID:
17664951
16.

Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution.

Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, Schuetz JD.

Cancer Res. 2007 Jul 15;67(14):6965-72.

17.

Uricase and other novel agents for the management of patients with treatment-failure gout.

Sundy JS, Hershfield MS.

Curr Rheumatol Rep. 2007 Jun;9(3):258-64. Review.

PMID:
17531181
18.

The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination.

Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D'Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O'Donnell CJ, Vasan RS, Wolf PA, Levy D.

Am J Epidemiol. 2007 Jun 1;165(11):1328-35. Epub 2007 Mar 19.

PMID:
17372189
19.

ATP-binding cassette, subfamily G (ABCG family).

Kusuhara H, Sugiyama Y.

Pflugers Arch. 2007 Feb;453(5):735-44. Epub 2006 Sep 16. Review.

PMID:
16983557
20.

Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.

Terkeltaub R, Bushinsky DA, Becker MA.

Arthritis Res Ther. 2006;8 Suppl 1:S4. Epub 2006 Apr 12. Review.

Supplemental Content

Support Center